Prednisolone

Generic Name: Prednisolone

Brand Names: Millipred Dp 6 Day

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₈O_₅

CAS Number: 50-24-8

Unique Ingredient Identifier: 9PHQ9Y1OLM

Background: Prednisolone is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.

Prednisolone was granted FDA approval on 21 June 1955.

Indication: Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Contact Dermatitis, Allergic Skin Reaction, Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonia, Aspiration Pneumonitis, Atopic Dermatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Burns, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Corneal injuries, Corneal ulceration, Crohn's Disease (CD), Cyclitis, Dermatomyositis (DM), Dermatosis of the Ear Canal, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Exacerbation of COPD, Exacerbation of asthma, Eye inflammation caused by Cataract Surgery, Eye inflammation caused by Infection, Fissure;Anal, Herpes Zoster Keratitis, Hot Water Burns (Scalds), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Inflamed External Hemorrhoid, Inflamed Hemorrhoids, Internal, Inflammatory Reaction caused by susceptible Bacterial Infections, Iridocyclitis, Iritis, Itching caused by susceptible Bacterial Infections, Keratitis, Loeffler's syndrome, Lymphoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Otic Eczema, Pemphigus, Perennial Allergic Rhinitis (PAR), Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Posterior Uveitis, Posttraumatic Osteoarthritis, Proctitis, Proteinuria, Pruritus, Pruritus Ani, Psoriatic Arthritis, Pulmonary Tuberculosis (TB), Pure Red Cell Aplasia, Rash, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Seasonal Allergic Rhinitis, Secondary Adrenal Insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Asthma, Sjogren's Syndrome (SS), Stevens-Johnson Syndrome, Superficial punctate keratitis, Synovitis, Systemic Lupus Erythematosus, Transplanted Organ Rejection, Trichinosis, Tuberculosis (TB), Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Rheumatic heart disease, unspecified, Acute Tenosynovitis, Anal eczema, Bacterial skin infections, Exfoliative erythroderma, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Primary adrenocoritical insufficiency, Severe Psoriasis, Severe Seborrhoeic dermatitis, Severe alcoholic liver disease, Steroid-responsive inflammation of the eye, Subacute Bursitis, Susceptible Bacterial Infections, Symptomatic Sarcoidosis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: -

Clinical Trials

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

Phase 3

Recruiting

Conditions: Prostate Cancer Metastatic

Interventions: Radiation: Stereotactic Ablative Body Radiotherapy (SABR)
Drug: Androgen Deprivation Therapy (ADT)
Other: 177Lu-PSMA-617
Drug: Niraparib and Abiraterone Acetate Dual Action Tablet DAT
Drug: Apalutamide
Drug: Androgen Receptor Signalling Inhibitor (ARSI)
Drug: Abiraterone Acetate
Radiation: Local Radiotherapy
Drug: Docetaxel
Drug: Prednisolone

First Posted Date: 2024-03-20

Last Posted Date: 2024-08-09

Lead Sponsor: University College, London

Target Recruit Count: 8000

Registration Number: NCT06320067

Locations: 🇬🇧
University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇬🇧
The Royal Marsden Hospital, Sutton, United Kingdom
🇬🇧
Royal Devon University Hospital Trust, Exeter, United Kingdom

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

First Posted Date: 2024-03-19

Last Posted Date: 2024-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 171

Registration Number: NCT06317662

A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)

Phase 1

Suspended

Conditions: Polymyalgia Rheumatica

Interventions: Drug: Prednisolone
Drug: SPI-62

First Posted Date: 2024-02-28

Last Posted Date: 2024-12-06

Lead Sponsor: Sparrow Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT06281236

Locations: 🇩🇪
Klinische Forschung Hannover Mitte GmbH/Pratia, Hannover, Germany
🇩🇪
Emovis Gmbh, Berlin, Germany
🇩🇪
Klinikum der Universität München, München, Germany

and more 2 locations

Efficacy and Safety of add-on Apremilast Versus add-on Methotrexate in Patients With Oral Lichen Planus

Phase 4

Not yet recruiting

Conditions: Oral Lichen Planus

Interventions: Drug: Prednisolone
Drug: Apremilast
Drug: Methotrexate

First Posted Date: 2024-02-15

Last Posted Date: 2024-02-15

Lead Sponsor: All India Institute of Medical Sciences, Bhubaneswar

Target Recruit Count: 64

Registration Number: NCT06260904

Locations: 🇮🇳
AIIMS Bhubaneswar, Bhubaneswar, Odisha, India

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

Phase 3

Recruiting

Conditions: DLBCL - Diffuse Large B Cell Lymphoma

Interventions: Drug: Rituximab
Drug: Dexrazoxane
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisolone
Drug: Lenalidomide
Drug: Pegfilgrastim

First Posted Date: 2024-01-23

Last Posted Date: 2024-08-19

Lead Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland

Target Recruit Count: 324

Registration Number: NCT06220032

Locations: 🇳🇱
NL-Breda-AMPHIA, Breda, Netherlands
🇳🇱
NL-Almelo-ZGTALMELO, Almelo, Netherlands
🇳🇱
NL-Amstelveen-AMSTELLAND, Amstelveen, Netherlands

and more 22 locations

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Phase 3

Recruiting

Conditions: Primary Mediastinal Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide Phosphate
Drug: Prednisolone
Drug: Rituximab
Drug: Vincristine Sulfate
Drug: Filgrastim
Drug: Pegfilgrastim
Drug: Nivolumab 40 mg in 4 ml Injection

First Posted Date: 2024-01-03

Last Posted Date: 2024-01-03

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 100

Registration Number: NCT06188676

Locations: 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation

A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis

Phase 3

Recruiting

Conditions: Allergic Bronchopulmonary Aspergillosis

Interventions: Drug: Prednisolone
Drug: Itraconazole

First Posted Date: 2023-12-18

Last Posted Date: 2024-04-17

Lead Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

Target Recruit Count: 300

Registration Number: NCT06174922

Locations: 🇮🇳
Chest Clinic, Dept. of Pulmonary Medicine, Chandigarh, India

Role of Extended Low Dose Prednisolone in Achieving Clinical and Biochemical Remission in Steroid Responsive Severe Alcoholic Hepatitis

Not Applicable

Not yet recruiting

Conditions: Severe Alcoholic Hepatitis

Interventions: Drug: Prednisolone
Drug: Placebo
Other: Standard Medical therapy

First Posted Date: 2023-12-04

Last Posted Date: 2023-12-04

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 150

Registration Number: NCT06155760

Locations: 🇮🇳
Institute of Liver & Biliary Sciences (ILBS), New Delhi, Delhi, India

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

Phase 3

Recruiting

Conditions: Chronic Graft Versus Host Disease

Interventions: Drug: Belumosudil
Drug: Placebo
Drug: Prednisone
Drug: Prednisolone

First Posted Date: 2023-11-22

Last Posted Date: 2024-12-06

Lead Sponsor: Sanofi

Target Recruit Count: 260

Registration Number: NCT06143891

Locations: 🇺🇸
Northwestern University- Site Number : 8400017, Chicago, Illinois, United States
🇺🇸
University of Kentucky Chandler Medical Center- Site Number : 8400024, Lexington, Kentucky, United States
🇺🇸
Karmanos Cancer Institute - Detroit- Site Number : 8400013, Detroit, Michigan, United States

and more 125 locations

A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)

First Posted Date: 2023-11-09

Last Posted Date: 2024-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 680

Registration Number: NCT06124157

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy